Author:
Alvarado Christine E.,Worrell Stephanie G.
Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. Shapiro J, Van Lanschot JJB, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.
2. National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers. Version 3.2023. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed 21 October 2023.
3. Rodriguez-Quintero JM, Kamel MK, Jindani R, et al. The effect of neoadjuvant therapy on esophagectomy for cT2N0M0 Esophageal Adenocarcinoma. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-14441-z.
4. Xiao X, Cheng C, Cheng L, Shang QX, Yang YS, Zeng XX, Hu Y, Chen LQ, Yuan Y. Longer time interval from neoadjuvant chemoradiation to surgery is associated with poor survival for patients without clinical complete response in oesophageal cancer. Ann Surg Oncol. 2023;30(2):886–96.
5. Qin Q, Xu H, Liu J, Zhang C, Xu L, Di X, Zhang X, Sun X. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis. Int J Surg. 2018;59:11–8.